RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
← catalyst calendarNCT06798896 · readout ≤ 377 d
Sponsored by Supernus Pharmaceuticals, Inc. (industry) · SUPN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
216estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-30 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Focal Onset Seizures
Interventions
- Drug: SPN-817
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period
measured Baseline and Maintenance Period (Maintenance Week 1-14)
Permalink · SUPN's whole pipeline · Catalyst calendar · Every registered study · What changed